The Selective COX-2 Inhibitor Etoricoxib Reduces Acute Inflammatory Markers in a Model of Neurogenic Laryngitis but Loses Its Efficacy With Prolonged Treatment
Inflammation Research - Switzerland
doi 10.1007/s00011-010-0185-5
Full Text
Open PDFAbstract
Available in full text
Date
March 28, 2010
Authors
Publisher
Springer Science and Business Media LLC